Nobel Prize-Winning Neuroscientist to Speak at UCSD January 10

 

January 04, 2007  |  

Dr. Paul Greengard, head of the Laboratory of Molecular and Cellular Neuroscience at The Rockefeller University and co-recipient of the 2000 Nobel Prize in Physiology or Medicine, will speak at the University of California, San Diego (UCSD) on Wednesday, January 10th at 11:00 a.m.

His lecture, "Signal transduction pathways used by therapeutic agents and drugs of abuse," is sponsored by the UCSD Neurosciences Graduate Program and Department of Pharmacology. The free lecture is open to the public, and will be presented at Mandeville Auditorium on the UCSD campus in La Jolla.

Greengard, Eric Kandel and Arvid Carlsson were awarded the Nobel Prize for their discoveries concerning signal transduction in the nervous system.  Greengard’s work has contributed to the understanding of how dopamine and a number of other neurotransmitters – specialized chemical messengers that send signals from one cell to another – work in the central nervous system.  Signaling abnormalities by dopamine are associated with several neurological disorders, including Parkinson's disease, schizophrenia, attention deficit hyperactivity disorder, and substance abuse. 

He has also shown that many of the therapeutic and toxic effects of several classes of common antipsychotic, hallucinogenic and antidepressant drugs can be explained in terms of the distinct neurochemical actions by which they affect the transmission of nerve signals in the brain.

Funding for the lecture was provided in part by a Neuroplasticity of Aging Training Grant from the National Institutes of Health.  For more information please contact Lisa Kurtz at lmkurtz@ucsd.edu

# # #

Media Contact: Debra Kain, 619-543-6163, ddkain@ucsd.edu 

 


Related Specialties

Neurosciences


Media Contact

Share This Article


Related News

6/15/2017
NASA has selected Alan Hargens, PhD, professor of orthopedic surgery at UC San Diego School of Medicine, to receive a 2017 Distinguished Public Service Medal.
6/15/2017
University of California San Diego School of Medicine has entered a five-year strategic partnership with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnso ...
6/9/2017
Radiation therapy (RT) using high-energy particles is a common and critical component in successfully treating patients with brain tumors but it is also associated with significant adverse effects. In ...
6/7/2017
Lesions of the appendix are being over diagnosed as invasive cancer, report University of California San Diego School of Medicine researchers in a paper published June 7 in the journal PLOS ONE.



Follow Us